• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.

作者信息

Schwarz Michael, Kocher Florian, Niedersuess-Beke Dora, Rudzki Jakob, Hochmair Maximilian, Widmann Gerlig, Hilbe Wolfgang, Pircher Andreas

机构信息

Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.

Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19.

DOI:10.1016/j.cllc.2018.12.006
PMID:30635258
Abstract
摘要

相似文献

1
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.免疫检查点相关毒性的免疫抑制可导致非小细胞肺癌（NSCLC）患者发生耶氏肺孢子菌肺炎（PJP）：2例报告
Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19.
2
Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy.抗程序性死亡 1（anti-PD-1）治疗转移性非小细胞肺癌患者的嗜酸性粒细胞增多症。
Immunotherapy. 2019 May;11(7):577-584. doi: 10.2217/imt-2018-0128.
3
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.程序性死亡受体 1 抑制剂治疗非小细胞肺癌患者免疫相关性肺炎的预后影响及危险因素。
Clin Lung Cancer. 2019 Nov;20(6):442-450.e4. doi: 10.1016/j.cllc.2019.07.006. Epub 2019 Aug 1.
4
Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.尼伏鲁单抗治疗进展性转移性肺癌是否如其承诺的那样有效？20 家综合医院的疗效和安全性分析。
Lung Cancer. 2018 Jan;115:49-55. doi: 10.1016/j.lungcan.2017.11.008. Epub 2017 Nov 16.
5
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.纳武利尤单抗治疗非小细胞肺癌的免疫相关不良事件与疗效的相关性。
Lung Cancer. 2018 Jan;115:71-74. doi: 10.1016/j.lungcan.2017.11.019. Epub 2017 Nov 21.
6
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.纳武利尤单抗治疗晚期非小细胞肺癌日本患者的早期死亡分析。
Clin Lung Cancer. 2018 Mar;19(2):e171-e176. doi: 10.1016/j.cllc.2017.09.002. Epub 2017 Oct 13.
7
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.纳武利尤单抗和帕博利珠单抗治疗因不良反应需要中断治疗的晚期非小细胞肺癌患者的疗效：一项回顾性多中心分析。
Clin Lung Cancer. 2019 Jan;20(1):e97-e106. doi: 10.1016/j.cllc.2018.09.005. Epub 2018 Sep 22.
8
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.抗 PD-1 免疫检查点抗体诱发肺癌患者急性嗜酸性粒细胞肺炎的潜在机制。
Immun Inflamm Dis. 2019 Mar;7(1):3-6. doi: 10.1002/iid3.238. Epub 2018 Nov 21.
9
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.非小细胞肺癌中使用程序性死亡1和程序性死亡配体1抑制剂后肺炎的发生率：试验的系统评价和荟萃分析
Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.
10
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.免疫相关不良反应谱与 NSCLC 患者抗 PD1 免疫治疗疗效的相关性。
Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21.

引用本文的文献

1
pneumonia in stage IIIA lung adenocarcinoma with immune-related acute kidney injury and thoracic radiotherapy: A case report.伴有免疫相关急性肾损伤及胸部放疗的ⅢA期肺腺癌合并肺炎：一例报告
World J Radiol. 2024 Sep 28;16(9):482-488. doi: 10.4329/wjr.v16.i9.482.
2
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review.与免疫检查点抑制剂给药相关的机会性感染和免疫相关不良事件：一项叙述性综述。
Pharmaceuticals (Basel). 2023 Aug 9;16(8):1119. doi: 10.3390/ph16081119.
3
Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas.
实体癌或白血病/淋巴瘤靶向治疗的感染性并发症
Cancers (Basel). 2023 Mar 27;15(7):1989. doi: 10.3390/cancers15071989.
4
Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.与免疫检查点抑制剂相关的耶氏肺孢子菌肺炎：基于FAERS数据库对已发表病例报告的系统文献综述及不成比例分析
Front Pharmacol. 2023 Mar 15;14:1129730. doi: 10.3389/fphar.2023.1129730. eCollection 2023.
5
Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab.肺腺癌患者的肺孢子菌肺炎：帕博利珠单抗的早期副作用
Radiol Case Rep. 2022 Aug 17;17(10):3979-3981. doi: 10.1016/j.radcr.2022.07.083. eCollection 2022 Oct.
6
Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids.两名接受免疫检查点抑制剂和皮质类固醇治疗的患者发生肺孢子菌感染。
J Immunother Precis Oncol. 2020 Feb 10;3(1):27-30. doi: 10.4103/JIPO.JIPO_23_19. eCollection 2020 Feb.
7
[Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review].[肺癌患者的耶氏肺孢子菌肺炎：综述]
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):272-277. doi: 10.3779/j.issn.1009-3419.2022.101.14. Epub 2022 Mar 28.
8
Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.免疫检查点抑制剂相关肺炎的潜在发病机制及治疗选择的见解
Biomedicines. 2021 Oct 16;9(10):1484. doi: 10.3390/biomedicines9101484.
9
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.免疫失调相关感染：癌症免疫治疗的一种新出现的并发症。
Thorax. 2022 Mar;77(3):304-311. doi: 10.1136/thoraxjnl-2021-217260. Epub 2021 Oct 4.
10
Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies.免疫检查点抑制剂在 HIV/AIDS 患者中的应用：事实与争议。
Cells. 2021 Aug 27;10(9):2227. doi: 10.3390/cells10092227.